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Objective: To examine the influence of cannabis use on
long-termoutcomeinpatientswithafirstpsychoticepisode,
comparing patients who have never used cannabis with (a)
those who used cannabis before the first episode but
stopped using it during follow-up and (b) those who used
cannabis both before the first episode and during follow-
up. Methods: Patients were studied following their first ad-
mission for psychosis. They were interviewed at years 1, 3,
and 5. At follow-up after 8 years, functional outcome and
alcohol and drug abuse were recorded. Patients were clas-
sifiedaccordingtocannabisuse:25hadcannabisusebefore
their first psychotic episode and continuous use during fol-
low-up (CU), 27 had cannabis use before their first episode
but stopped its use during follow-up (CUS), and 40 never
used cannabis (NU). Results: The 3 groups did not differ
significantlyinsymptomsorfunctionaloutcomeat baseline
or during short-term follow-up. The CUS group exhibited
better long-term functional outcome compared with the
other 2 groups and had fewer negative symptoms than
the CU group, after adjusting for potential confounders.
For the CUS group, the effect size was 1.26 (95% confi-
dence interval [CI] 5 0.65 to 1.86) for functional outcome
and 20.72 (95% CI 52 1.27 to 20.14) for negative symp-
toms. All patients experienced improvements in positive
symptoms during long-term follow-up. Conclusion: Canna-
bis has a deleterious effect, but stopping use after the first
psychotic episode contributes to a clear improvement in
outcome. The positive effects of stopping cannabis use
can be seen more clearly in the long term.
Key words: cannabis/first-episode psychosis/outcome/
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Introduction
Theconsistent association between cannabis useand psy-
chosis establishes cannabis as a harmful drug, especially
in young people. Nevertheless, the nature of the associ-
ation is not fully understood. Some genetic factors prob-
ably predispose individuals to cannabis use, especially in
midadulthood.
1 More importantly, however, cannabis
use may act as an environmental factor that influences
age at onset of psychosis,
2,3 increasing the risk of devel-
oping psychosis both in the general population and, par-
ticularly, in vulnerable individuals,
4 as well as potentially
worsening the outcome of patients with psychosis.
5–7
Moreover, a greater brain volume reduction has been
demonstrated over a 5-year follow-up in patients with
schizophrenia who are cannabis users compared with
nonusers.
8
First-episode patients with schizophrenia who use can-
nabis have been reported to have a poorer outcome than
patients who do not use cannabis. In a systematic review,
the majority of 7 follow-up studies of first-episode psy-
chosis patients found that cannabis use was associated
with poorer outcomes in the short term and medium
term, although differences in outcome between cannabis
users and nonusers were more modest when the studies
controlled for the use of other drugs and baseline illness
severity.
9 In the 6-month follow-up study by Hides,
10
there was a poorer outcome in patients with a first psy-
choticepisode and cannabisuse, after adjustingforuse of
other drugs and baseline symptoms. Similar results were
found in another elegant study with a 15-month follow-
up.
11 Moreover, in a study comparing the effects of can-
nabisuseinfirst-episodemanicpatientswhobegantouse
cannabis before vs after their first episode, the percentage
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631oftimeinremission wasinverselyassociatedwiththe per-
centage of weeks with cannabis abuse.
12
Findings so far may seem pessimistic for patients with
comorbid cannabis use, and it can be inferred that one
or more of the components of cannabis, such as delta-
9-tetrahydrocannabinol,
13,14 may produce permanent
changes in the central nervous system. However, little
is known about outcomes in patients who quit using can-
nabis and in those who continue to use cannabis after
a first episode of psychosis. The issue is important as,
according to recent studies, about half of the patients
who use cannabis are able to cease cannabis use with
usual psychopharmacological treatments
6,15 and with
specific programs designed to prevent abuse.
16,17 Given
the high prevalence of substance misuse in first-episode
psychotic patients,
18 the outcome in patients who con-
tinue to use cannabis and in those who stop using canna-
bis should be investigated and differentiated from that of
patients who have never used cannabis. In a short-term
follow-up study with 110 early-onset first-episode psy-
chosis patients, a greater improvement in psychopathol-
ogy was seen in those who ceased using cannabis.
19
In a cohort of first-episode psychosis patients followed
for 8 years, we hypothesized that patients who continued
to use cannabis would have a poorer long-term outcome
and that those who stopped using cannabis would have
asimilar outcometo neverusers.Theaim ofthisprospec-
tive observational study was to examine the influence of
cannabis use on long-term outcome in patients with a re-
cent-onset first psychotic episode, comparing those
patients who used and then stopped cannabis with those
who never used cannabis and with those who continued
to use cannabis during follow-up.
Methods
Subjects
Data were gathered on recent-onset first-episode psycho-
sis patients admitted consecutively to a general hospital
psychiatric ward between February 1997 and January
1999. The hospital provides psychiatric care to all inhab-
itants (300 000) of the catchment area around Vitoria in
the Spanish Basque Country, regardless of their socio-
economic status. There is only one emergency room
for psychiatric patients, and, if necessary, patients are
hospitalized in the psychiatric department of the general
hospital as there are no other inpatient units (public
or private) in the area. Therefore, the study sample rep-
resents the entire population of patients with a first psy-
chotic episode who need inpatient psychiatric treatment.
Patients were enrolled in the study after providing
informed consent.
A first psychotic episode was defined as the first time
a patient displayed positive psychotic symptoms of delu-
sions and/or hallucinations. All subjects were aged 15–65
years and met the Diagnostic and Statistical Manual of
Mental Disorders (Fourth Edition) (DSM-IV)
20 criteria
for schizophreniform disorder, schizoaffective disorder,
schizophrenia, delusional disorder, brief psychotic disor-
der, psychotic disorder not otherwise specified, bipolar
disorder with psychotic features, or major depressive dis-
order with psychotic features. Subjects with mental retar-
dation or organic brain disorders were excluded from the
study, as were subjects with substance-induced psychotic
disorders. No subjects had shared psychotic disorder.
The DSM-IV axis I diagnosis was made using the Struc-
tured Clinical Interview for DSM-IV (SCID-I).
21
Patients with positive symptoms lasting longer than 6
months were excluded from the study.
Assessments
After admission, patients with first-episode psychotic
symptoms were assessed using a protocol that included
the SCID-I, urine drug screens (including cannabis deriv-
atives), and the following clinical scales: the Positive and
Negative Symptoms Scale (PANSS),
22 the Hamilton De-
pression Rating Scale (HDRS)-21,
23 the Young Mania
Rating Scale (YMRS),
24 the Phillips Premorbid Adjust-
ment Scale,
25 and the Global Assessment of Functioning
(GAF),
26 which was used to assess general functioning.
The original GAF instructions call for rating of symp-
toms or functioning, but as symptoms were already eval-
uated with other scales, the raters were trained to
evaluate psychosocial functioning, as in some previous
studies.
27 The Addiction Severity Index (ASI) and
SCID-I were administered at every visit (baseline and
1, 2, 3, 4, 5, and 8 y). This ASI is based on a 9-point scale
(0–1, no real problem; 2–3, slight problem, substance
abuse treatment probably not necessary; 4–5, moderate
problem, some treatment indicated; 6–7, considerable
problem,treatmentnecessary;and8–9,extremeproblem,
treatment absolutely necessary). Using the information
obtainedfrom the patient,the key informant, themedical
record, and drug screens, we determined whether the pa-
tient had used cannabis, how often the patient had used
cannabis, and when that use had occurred. This informa-
tion on cannabis use was grouped into 4 categories: no
use, use, abuse, and dependence (table 1). The same
method was used to establish use, abuse, or dependence
of other drugs and of alcohol. Other relevant clinical and
demographic variables were also collected, ie, gender,
age, civil status, residential status, and comorbidity
with alcohol and/or drug abuse. The evaluations were
performed during a clinical interview that lasted about
90 minutes and pertained to the previous week. The in-
terview was conducted by 2 psychiatrists (A.G.-P.; F.M.)
who had good interrater reliability for SCID-I diagnoses
(j=0.88)andforthescalesused(PANSS,j=0.80;GAF,
j = 0.95; Phillips Premorbid Scale, j = 0.77; YMRS, j =
0.83; HDRS-21, j = 0.79).
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abuse was blind to the clinical ratings; they discussed
any inconsistencies and selected the most reliable source.
Cannabis use was defined according to DSM-IV using
SCID-I,
21 ASI, and the information obtained from urine
analyses.
At years 1, 3, and 5, patients were evaluated by direct
interview using the same methods as those used at base-
line,obtaininginformationusingtheGAF,PANSSpos-
itive, PANSS negative, YMRS, and HDRS-21. At year
8, only the GAF was completed, which evaluated psy-
chosocialfunctioningfromthepreviousvisittothepres-
ent visit. Hospitalizations were recorded at all visits.
Patients were also interviewed using the SCID-I and
the ASI every second year (ie, at years 2 and 4), and
urine analyses were performed. A patient was defined
as a cannabis user if, during follow-up, they took can-
nabis at least 4 times in the previous year and once in the
month before each interview. The first 5 years of follow-
up ended in January 2004. Patients who could not be
contacted during the study period were considered
lost to follow-up.
Other drugs of use or abuse were most commonly co-
caine and amphetamines. With regard to treatment for
psychosis, all patients received pharmacological treat-
ment, mainly low doses of atypical antipsychotics,
according to clinical guidelines and irrespective of canna-
bis use status. The majority of patients were treated with
monotherapy (61/92, 66.3%), and one-third were treated
with 2 or more drugs at some point during the study (31/
92, 33.7%). Use of polytherapy did not differ between the
cannabis use groups (P = .483). Similarly, use of benzo-
diazepines did not differ among groups (P = .742).
Patients received standard care at their community
mental health center after hospital discharge, usually
one visit per month. They received family interventions,
if required, and psychological support. More care was
prescribed if needed, and hospitalizations were available
for all patients who required them, irrespective of socio-
economic status. If immediate attention was needed, an
emergency room was available on a 24-hour basis.
The study was approved by the Ethics Committee
(Institutional Research Board) of Santiago Hospital.
Patient Classiﬁcation
Patients were classified according to their cannabis use
into 1 of 3 groups: (1) patients who had never used can-
nabis (NU); (2) patients who used cannabis before the
baseline evaluation and continued to use it throughout
the follow-up period (CU), including those who began
using cannabis during follow-up (1 patient) and those
who stopped cannabis use and then started it again
(4 patients); and (3) patients who used cannabis before
the baseline evaluation but stopped using it definitively
during the follow-up period (CUS), including 1 patient
who began to use cannabis in year 1 but stopped defin-
itively in year 2. This classification was determined
by integrating baseline and follow-up information on
the same variables. Of the patients in the CUS group,
85.2% (23/27) stopped using cannabis in the first 3 years
of follow-up and 14.8% (4/27) stopped in the fourth
year.
The same procedure was used to classify patients into 3
groups for other drug use (other drugs NU, other drugs
CU, other drugs CUS) and for alcohol abuse (alcohol
abuse NU, alcohol abuse CU, alcohol abuse CUS), so
the effect of such substance abuse could be taken into ac-
count in the analyses.
Statistical Analyses
The primary outcome variable was functional outcome
measured using the GAF, and the secondary outcome
variables were positive and negative symptoms measured
using the PANSS. Baseline sociodemographic and clini-
cal characteristics for the total sample and by cannabis
use group were described using frequencies and percen-
tages for the categorical variables and means and SDs
or medians and interquartile ranges for the continuous
variables, depending on the distributional characteristics
of each variable. Comparisons among the 3 cannabis use
groups were made using v
2 tests or the Fisher exact test
for categorical data and the analysis of variance
(ANOVA) test or Kruskal-Wallis test for continuous
data, depending on whether normality and size assump-
tionsheld.Furthermore,anydifferencesbetweenpatients
followed up for less than 5 years vs those followed up for
more than 5 years were analyzed using v
2 tests, Fisher
exact tests, Student t tests and Mann-Whitney tests, as
appropriate.
Table1. InformationUsedtoDefinethe4CategoriesofCannabis
Use
Cannabis
Use
DSM-IV Abuse or
Dependence Cannabis
ASI Cannabis
Scores
Dependence Meet minimal or more
DSM-IV criteria for
cannabis dependence
8–9
Abuse Meet  1 criteria for
cannabis abuse
4–7
Use Abuse criteria but do
not meet temporal
criteria (at least 12 mo)
or use 12 mo but not
fulﬁlling any criteria of
DSM-IV abuse
2–3
Not use No signiﬁcant symptoms 0–1
Note: DSM-IV, Diagnostic and Statistical Manual of Mental
Disorders (Fourth Edition); ASI, Addiction Severity Index.
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Cannabis First-Episode Psychosis: Long-term OutcomeAnalyses of Clinical and Functional Outcomes. Differen-
cesin clinical and functional outcomethroughoutthe fol-
low-up period were assessed using mixed-effects models
for the analyses of repeated-measures data. The response
variables were the scores obtained for each scale (GAF,
PANSS positive, and PANSS negative) at each evalua-
tion. The approach comprised a 3-step procedure. First,
to analyze the apparent individual effect that stopping
cannabis use may have on outcome, univariate mixed ef-
fect models were fitted using time, cannabis group, and
the interaction term. In the second step, the same mod-
eling approach was used to assess the individual effect of
other variables on the response variables; the variables
evaluated were gender, age, civil status, as well as the ef-
fect of stopping other drug use and stopping alcohol
abuse. When the ANOVA test for the corresponding
terms had a P value <.1, they were included in the final
model together with cannabis use. Finally, multivariate
mixed-effect models were fitted, which included the can-
nabis group, the confounding variables selected in the
second step, the continuous variable time, and the appro-
priate interaction terms. The CUS group was used as the
reference category to facilitate interpretation and com-
parisons. All models included a random effect to account
for the repeated-measure structure of the data and were
fitted using maximum likelihood techniques assuming
normality in the error term. Diagnosis of the models
was carried out to assess whether or not the underlying
normality assumptions held. Additionally, the same
methodology was used to assess short-term outcome
but considered only baseline values and data at 1-year
follow-up.
All statistical analyses were carried out using the sta-
tistical package R 2.5.1.
28
Results
Study Sample and Baseline Characteristics
Patients were included in the analysis if they were fol-
lowed up for at least 5 years. Of the 127 patients with
a first psychotic episode, 15 did not meet the inclusion
criteria: They were excluded due to organic disease
(n = 5), a diagnosis of drug-induced psychosis (n = 4),
and not giving informed consent (n = 6). Of the 112
patients enrolled at baseline, 92 (82%) were followed
up for at least 5 years and comprise the total study sam-
ple; 82 patients were interviewed at 8-year follow-up.
The mean (6SD) age of the patients at baseline was
29.78 6 10.77 years (range, 16–61 y), and 45 (48.9%)
were women. The sociodemographic characteristics
and baseline clinical data of the study sample are given
intable 2. Ofthe total sample(n= 92),56%were cannabis
users at baseline.
The cannabis use groups consisted of a large group of
never users (NU, 40/92, 43.5%), followed by 2 similarly
sizedgroupsofcontinuoususers(CU,25/92,27.2%)and
use and stop patients (CUS, 27/92, 29.3%). The latter 2
groups of cannabis users had similar severity of canna-
bis use at baseline: About 88.9% (24/27) of patients in
the CUS group and 92% (23/25) of the CU group met
Table 2. Sociodemographic and Baseline Clinical Data of the Total Sample and by Cannabis Use Group
Total (n=92)
Never Used
(n = 40)
Continued to
Use (n = 25)
Used and Stopped
(n = 27) P Value
Gender
Female 45 (48.9%) 21 (52.5%) 12 (48%) 12 (44.4%) v
2 = 0.43 (P = .807)
Male 47 (51.1%) 19 (47.5%) 13 (52%) 15 (55.6%)
Age, y 29.78 6 10.77 35.43 6 12.59 26.00 6 5.99 24.93 6 6.91 F = 12.17 (P < .001)
Civil status
Married 16 (17.4%) 12 (30%) 1 (4%) 3 (11.1%) v
2 = 8.28 (P = .016)
Other 76 (82.6%) 28 (70%) 24 (96%) 24 (88.9%)
Residency
With relatives 69 (75%) 31 (77.5%) 19 (76%) 19 (70.4%) Fisher (P = .29)
Alone 8 (8.7%) 4 (10%) 0 (0%) 4 (14.8%)
Other 15 (16.3%) 5 (12.5%) 6 (24%) 4 (14.8%)
Philips 5.63 6 3.01 5.60 6 3.70 6.04 6 2.30 5.30 6 2.45 F = 0.39 (P = .67)
PANSS positive 24.76 6 6.86 23.63 6 6.88 25.44 6 6.96 25.81 6 6.74 F = 0.99 (P = .37)
PANSS negative 18.88 6 9.39 19.13 6 10.00 16.96 6 9.06 20.30 6 8.79 F = 0.84 (P = .43)
GAF 55.18 6 13.17 56.13 6 13.50 55.08 6 14.04 53.89 6 12.18 F = 0.23 (P = .79)
Alcohol abuse 49 (53.3%) 11 (27.5%) 19 (76%) 19 (70.4%) Fisher (P < .001)
Drugs 30 (32.6%) 3 (7.5%) 16 (64%) 11 (40.7%) Fisher (P < .001)
Note: PANSS, Positive and Negative Symptoms Scale; GAF, Global Assessment of Functioning.
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A. Gonza ´lez-Pinto et al.the criteria for abuse or dependence at baseline, whereas
only 7.4% (2/27) of the CUS group and 4% (1/25) of the
CUgroupusedcannabiswithoutmeetingthecriteriafor
abuse or dependence. At year 8, the frequency of canna-
bis use, abuse, and dependence in the CU group was
16% (4/25), 56% (14/25), and 28% (7/25), respectively.
There were no significant differences between the can-
nabis use groups with respect to diagnoses (Fisher, P =
.54), but some sociodemographic variables differed be-
tween groups. Patients in the NU group were more fre-
quently married and were older compared with the CU
and CUS groups (table 2). The differences between the
NU and CU groups and between the NU and CUS
groups were significant (P < .001 in both cases).
At baseline, there were no significant differences be-
tween the 3 groups in premorbid adjustment, positive
or negative symptoms, or functioning. Rates of both al-
coholabuseand otherdrugabuseweresignificantlyhigh-
er in the CU and CUS groups, compared with the NU
group (table 2).
Follow-up Data and Comparisons Between Patients With
and Without Long-term Follow-up. The mean duration
of follow-up was 7.67 6 0.94 years. The mean number
of hospitalizations for the total sample was 3.39 6
4.50. The total number of hospitalizations did not differ
significantly among the 3 cannabis use groups (Kruskal-
Wallis = 3.273, P= .195; means: 2.48 6 3.04 for NU, 5.50 6
7.51 for CU, 3.22 6 2.80 for CUS).
The 3 cannabis use groups reduced their alcohol and
drug intake during follow-up. At the end of the study,
19.5% (18/92) of the total sample were abusing alcohol,
and 9.2% (10/92) were using other drugs. Medication ad-
herence did not differ between the cannabis use groups
(v
2 = 3.84, P = .06, for CUS vs NU; v
2 = 1.23, P =
.268, for CUS vs CU).
There were no differences between patients followed
up for at least 5 years and those with a shorter follow-
up with respect to baseline symptoms and cannabis use
group: age (t =  0.622, P = .535), gender (v
2 = 0.986,
P = .321), civil status (Fisher, P = .750), residential status
(Fisher, P = .409), and cannabis use (Fisher, P = .252).
Clinical and Functional Outcomes During Follow-up by
Cannabis Use Group
UnivariateModels. The evolution of the GAF, PANSS
positive, and PANSS negative scores over time by canna-
bis use group are shown in figures 1–3. The univariate
models fitted in the first step showed that the cannabis
group variable was significant on both the GAF scores
(F2,332 = 9.938, P < .001) and the PANSS negative scores
(F2,241 = 4.828, P = .009) but not on the PANSS positive
scores(F2,241= 0.436,P=.647).These univariateanalyses
showeda significantimprovement (reduction) from base-
line in PANSS positive scores in all 3 cannabis use groups
(all P‘s <.001) (figure 2), whereas only the CUS group
showed a significant improvement (increase) in the
GAF score (figure 1, CUS, b = 1.902, P < .001; CU,
b =  0.271, P = .465; NU, b = 0.262, P = .370). There
was a significant improvement (reduction) in the PANSS
negative scores in the CUS group only, while the CU
group showed a nonsignificant trend to increase (figure
3, CUS, b =  0.965, P = .012; NU, b =  0.392, P =
.226; CU, b = 0.744, P = .069). Regarding the affective
symptoms, the univariate models showed that the canna-
bis group variable was not significant on the HDRS-21
scores (F2,236 = 0.535, P = .587) or on the YMRS scores
(F2,240 = 0.855, P = .427).
Fig. 1. Global Assessment of Functioning (GAF) Outcome by
Cannabis Use Group.
Fig. 2. Positive and Negative Symptoms Scale (PANSS) Positive
Symptoms Outcome by Cannabis Use Group.
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Cannabis First-Episode Psychosis: Long-term OutcomeIn the second step of the analysis, the univariate mod-
els showed that gender, age, and civil status did not have
a significant effect on any of the outcome measures,
whereasotherdruguseandalcoholabusehadasignificant
effect on the GAF score only (other drug use, ANOVA
F2,332 = 5.772, P = .003; alcohol abuse, F2,332 = 6.597,
P = .002). This indicated that stopping alcohol abuse
and stopping other drug use significantly increased the
GAF score (ie, improved functioning). On the other
hand, quitting alcohol abuse or ceasing use of other drugs
didnothaveasignificanteffectonthePANSSpositiveand
PANSSnegativescores(allANOVAPvaluesweregreater
than .1).
Multivariate Models. The results of the multivariate
mixed-effect models for PANSS positive, PANSS nega-
tive, and GAF evolution assessments are given in table 3.
For GAF, all substance use variables (cannabis, alco-
hol, and other drugs) were significant in the second step
oftheanalysesandsowereincludedinthefinalmodel.At
baseline, the GAF scores did not differ significantly be-
tween the reference group (CUS) and the other 2 canna-
bis use groups (CU and NU). Similar nonsignificant
resultswereobtainedforthecomparisonbetweencatego-
ries of other drug use and alcohol abuse at baseline
(table 3). In contrast, the changes in GAF scores during
follow-up differed significantly between the groups. For
the cannabis use groups, the slope of the curve for the
Fig. 3. Positive and Negative Symptoms Scale (PANSS) Negative
Symptoms Outcome by Cannabis Use Group.
Table 3. Results Derived From the Mixed Effect Models of the Evolution for the Scales PANSS Positive, PANSS Negative, and GAF by
Group
Variable Parameter (*)
GAF PANSS Negative PANSS Positive
b P Value b P Value b P Value
Baseline
Intercept (reference = CUS group for all variables) 57.70 <.001 17.61 <.001 21.23 <.001
Cannabis
CU group (vs reference) 1.60 .70  2.64 .21 0.01 .99
NU group (vs reference) 3.78 .36  0.42 .82  0.78 .61
Other drugs
CU group (vs reference) 0.03 .99 Not included Not included
NU group (vs reference)  0.56 .88 Not included Not included
Alcohol abuse
CU group (vs reference)  2.06 .60 Not included Not included
NU group (vs reference)  3.16 .41 Not included Not included
Follow-up
Time (reference = CUS evolution for all variables) 2.10 <.001  0.96 .01  2.15 <.001
Cannabis
Time* CU (vs reference)  1.43 .01 1.70 .00 0.54 .36
Time* NU (vs reference)  1.42 .01 0.57 .25 0.16 .76
Other drugs
Time* CU (vs ref)  1.59 .02 Not included Not included
Time* NU (vs reference) 0.14 .78 Not included Not included
Alcohol abuse
Time* CU (vs reference)  0.58 .31 Not included Not included
Time* NU (vs reference)  0.73 .17 Not included Not included
Note: GAF, Global Assessment of Functioning; PANSS, Positive and Negative Symptoms Scale. Asterisk—the reference categories are
continuous use and stop (CUS) groups for cannabis, for other drug use, and for alcohol abuse, whereas groups CU and NU refer to
continuous use and never use for the same 3 substances.
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.001), indicating an increase in GAF over time. For the
CU and NU groups, the GAF outcome was significantly
different from the CUS group (b =  1.438, P = .014, for
CU and b =  1.421, P = .016, for NU). In addition, con-
tinuous use of other drugs had a worse effect on the GAF
outcome compared with stopping other drugs (b =
 1.598, P = .025). No other significant between-group
changes were observed (table 3). The effect size for the
CUS group was 1.26 (95% confidence interval [CI] =
0.65 to 1.86).
For the PANSS negative subscale, only cannabis use
was statistically significant in the univariate models, so
the univariate and multivariate models did not differ.
At baseline, there were no significant differences in
PANSS negative scores between the cannabis use groups.
During follow-up, however, there were between-group
differences on this scale. In the CUS group, the PANSS
negative score decreased significantly (b =  0.965, P =
.012). The changes in the PANSS negative score of the
CUS group differed significantly from those of the CU
group (b = 1.709, P = .003) but not from those of the
NU group (b = 0.573, P = .253). The effect size for the
CUS group was  0.72 (95% CI =  1.27 to  0.14).
Finally, the analyses carried out to assess if the afore-
mentioned differences among groups were also observed
in the short term showed that stopping cannabis use had
no influence on short-term outcome. The results were
similarforall3outcomemeasures:Theoutcomewaspos-
itive and highly significant for the whole sample regard-
less of cannabis use group (for GAF, F1,84 = 13.464, P <
.001; for PANSS negative, F1,78 = 18.351, P < .001; for
PANSS positive, F1,78 = 88.127, P < .001), whereas the
cannabis group effect was not significant on any of the
changes in scores (for GAF, F2,84 = 0.465, P = .630;
for PANSS negative, F2,78 = 0.344, P = .710; for PANSS
positive, F2,78 = 1.041, P = .358).
Discussion
The most important finding of this study is that the func-
tionaloutcome ofCUSpatientsimprovedmorethanthat
of NU patients. Moreover, the functional outcome of
CUS patients improved progressively, while their nega-
tivesymptomsdiminishedsignificantly.Thesedifferences
were apparent in the long term but not after 1 year of
follow-up. Consistent with our hypothesis, continued
useofcannabis(CU)hadadeleteriouseffectonoutcome.
CU patients only improved in their positive symptoms
and showed a nonsignificant tendency to increase their
negative symptoms. Taking all the findings together,
and considering that the influence of other potential fac-
tors (such as other drug use and alcohol abuse) was also
evaluated, we conclude that cannabis has a complex ef-
fect on patients with psychosis. In addition, both the neg-
ative effect of continuous cannabis use and the positive
effects of cannabis cessation can be seen more clearly
in the long term, with the differences between groups be-
ing more marked after 3 years of follow-up.
To our knowledge, this is the first study that has mea-
sured long-term functional outcome while controlling for
use of alcohol and other drugs and in which those
patients who are able to stop using cannabis are sepa-
rated from those who cannot do so. In the only previous
study that separated patients with recent-onset psychosis
into groups based on duration of cannabis use, the
patients who continued to use cannabis over the 4-year
follow-up had a more chronic course of disease.
29 In ad-
dition, those patients who used cannabis but stopped us-
ing it during follow-up had fewer negative symptoms,
although the difference was not significant.
29 Further-
more, in a group of children and adolescents with a first
psychoticepisodefollowedup for6months,quittingcan-
nabiswas associated witha better outcome.
19 Other stud-
ies evaluating functional outcome in patients with a first
psychotic episode and continued use of cannabis gener-
ally found a worse outcome in such patients.
15,30
As in a previous study,
31 cannabis users (both CU and
CUS) were not distinguishable from nonusers with re-
specttopremorbidadjustment orbaseline symptoms. Al-
though some previous studies found slight short-term
increases in positive symptoms with cannabis use, these
weregenerallymodestwhenadjustedforothervariables.
9
As previously reported,
15 we found a greater reduction in
positive and negative symptoms and an improvement in
functional outcome in the first year in all groups. How-
ever, only patients who used and then stopped using can-
nabis (CUS) had significant reductions in negative
symptoms in the long term. Patients who continued to
use cannabis (CU) did not experience reductions in their
negative symptoms, so it is questionable that they used
cannabis to diminish negative symptoms, as proposed
by the self-medication hypothesis.
32 Likewise, functional
outcome was clearly improved after 8 years of follow-up
in patients who stopped using cannabis. Indeed, there
was a cannabis time improvement interaction with re-
specttofunctionaloutcomeintheCUSgroup,withapro-
gressive improvement during follow-up. Therefore, there
seems to be an association between cannabis use and
worseoutcome,althoughthedirection ofthe relationship
(ie, causality) is not known due to the naturalistic design
of the study.
Just over half of the total sample (56%) used cannabis
at baseline, which is similar to the rate reported by Veen
et al
2 (52%) in their incident sample. Also, a comparative
general population study found that cannabis use was
similar in Arizona and Spain.
33 Consistent with a previ-
ousstudy,
6wefoundthatallbut2ofthecannabisusersin
our sample used cannabis before their first psychotic ep-
isode was diagnosed. However, the temporal pattern of
cannabis use may vary from country to country; eg, in
a UK study, a subgroup of patients stopped cannabis
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29 Also, in a well-
designed study comparing different types of cannabis
use, some patients began to use cannabis after their first
episode of mania.
12 Some of the differences noted be-
tween studies could be related to the age of the patients
and to the sample size.
The majority of our sample was only able to quit using
cannabis after 3 years of follow-up. Thus, it is probably
only at this stage that a decision can be made about the
need for specific treatment for patients who continue to
use cannabis. Our results are in line with previous find-
ings that almost half of the patients receiving psycho-
pharmacological treatment are able to cease cannabis
abuse after 2 years of treatment.
15 Similarly, in the Eu-
ropean Mania in Bipolar Longitudinal Evaluation of
Medication study, cannabis use was overrepresented in
first-episode manic patients, compared with patients
who had experienced multiple episodes.
34
The deleterious effect of continued cannabis use on
symptoms and functional outcome could, in part, be
explained as an additive effect of psychosis and cannabis
use. Use of other drugs, mainly stimulants, also contrib-
utes to worsening functional outcome. It is difficult to
understand why those patients who were able to quit can-
nabis use during follow-up had a better long-term func-
tional outcome than those who never used cannabis. It
could be that at initial hospitalization with a first psy-
chotic episode, cannabis users have a phenotypic presen-
tation that is as severe as nonusers (although they could
have a lower genetic loading) but that quitting cannabis
reveals a more benign disease after some years of follow-
up, at least for functional outcome and negative symp-
toms. If so, continued use of cannabis causes even
more damage than is currently thought. The progressive
improvement of both symptoms and functioning during
follow-upintheCUSgroupisnotconsistentwiththethe-
ory that cannabis causes permanent and residual effects
in the long term. As cannabis use among patients with
a first psychotic episode is associated with a greater brain
volume loss than in nonusers, it would be interesting to
monitor the long-term brain volume of patients who
cease using cannabis after a first psychotic episode. Cu-
riously, in the study by Rais et al,
8 half of the nonuser
patients had used cannabis prior to their baseline evalu-
ation. It would also be interesting to analyze separately
those patients who were able to quit cannabis use and
those who never used cannabis.
Furthermore, as already proposed,
35 there might be
some interaction between cannabis and antipsychotic
treatment that results in reduced antipsychotic efficacy.
Although such an interaction may play a role, we did
not find any differences between cannabis use groups
in the area where antipsychotics are most effective, ie,
positive symptoms.
Severallimitationsofthisstudyshouldbetakenincon-
sideration. First, the number of patients included was
limited, which can produce type II errors (wrongly con-
cluding that there is no difference between groups when
there is a difference). Nevertheless, the rates of follow-up
were very high despite the long follow-up period (8 y).
Second, the results cannot be generalized to first-episode
patients who do not need hospital admission or to
patients with cannabis- or drug-induced psychosis. How-
ever,the useofapopulation-basedinpatientsamplegives
strength to the results. Third,asthecannabiscomposition
varies slightly between batches, it is impossible to deter-
minetheactualamountofcannabisconsumedbyeachpa-
tient.Weestimatedtheamountofcannabistakenfromthe
informationprovidedbythepatientsandtheirrelativesin
the semistructured interviews, and cannabis use was con-
firmedbyurineanalysescarriedoutatleastonceayearin
the entire sample. This method, and the high rates of can-
nabisandalcoholusewithinthesample,suggeststhatbias
in the estimates of cannabis use is minimal.
Despite these potential limitations, this is the first
study of patients with recent-onset psychosis to consider
patients who use and then stop using cannabis as a sepa-
rate group, as well as controlling for comorbid use of al-
cohol and other drugs.
In conclusion, half of the patients with a first psychotic
episodewhousedcannabiswereabletostopusingitduring
follow-up.Thosepatientswhostoppedusingcannabisex-
periencedaslowbutsteadyimprovementovertimebothin
functionaloutcomeandnegativesymptoms.Ontheother
hand, patients who continued using cannabis had a trend
to increasing negative symptoms over time and no im-
provement in functional outcome. All patients had
improvements in positive symptoms over the long term.
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